We are BioSyntex, a small, woman-owned drug discovery and design company making strides in novel therapeutics.  We align with a progressive vision in the biomedical field.


Synalar is formulated with fluocinolone acetonide, a synthetic corticosteroid renowned for its anti-inflammatory properties. When applied, it interacts with the body in a multifaceted way, leading to several therapeutic effects. Specifically, it causes the blood vessels to constrict, thereby limiting blood flow to the inflamed area. Furthermore, it reduces the permeability of cell membranes, inhibits mitotic activity (cell division), suppresses the immune response, and prevents the release of substances that trigger inflammation.

Virginia Coquilla played a vital role in synthesizing fluocinolone acetonide, the essential ingredient in Synalar. Her contribution to this topical corticosteroid has enabled it to become an effective treatment for various skin conditions, such as eczema, dermatitis, psoriasis, allergies, rash, burns, and insect bites. Through its intricate mechanisms of action, Synalar represents a significant advancement in managing skin inflammations and offers a testament to Virginia Coquilla’s expertise in the field of chemistry. The formulas have been patented several times by pharmaceutical giants and prescribed by physicians worldwide, reflecting their groundbreaking potential in the treatment of various complex diseases.